ATAKAN TOPCU, MEHMET BESİROGLU, MUHAMMED MUSTAFA ATCİ, SABAN SECMELER, MURAT AYHAN, METİN OZKAN, OKTAY BOZKURT, ZUHAT URAKCİ, SEVAL AY, CAGLAYAN GEREDELİ, AYSE IREM YASİN, OZGE PASİN, HACİ MEHMET TURK
Eurasian Journal of Medical Investigation - 2023;7(2):153-161
Objectives: To compare the second-line treatments on survival after trastuzumab failure in HER2-positive metastatic gastric cancer. Methods: We retrospectively included 57 patients. Of whom, 32 (56%) received paclitaxel, whereas 25 (44%) received 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI). We analyzed the patient characteristics, and survival outcomes of the second-line treatment. Results: The median PFS was 3.5 months in the paclitaxel-group and 4.8 months in the FOLFIRI-group (p=0.569). The median overall survival (OS) was 6.0 months in paclitaxel-group and 11.0 months in FOLFIRI-group (p=0.410). FOLFIRI provided a significant OS advantage over paclitaxel in patients with grade 3 tumors or who did not have an objective first-line treatment response. Conclusion: FOLFIRI may be recommended as a preferred option over paclitaxel in patients with these identified risk factors.
